Last update 21 Apr 2025

Teplizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
hOKT3-gamma-1-ala-ala, hOKT3-γ1-ala-ala, Teplizumab (USAN/INN)
+ [7]
Target
Action
inhibitors
Mechanism
CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors)
Inactive Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (17 Nov 2022),
RegulationPriority Review (China), Priority Review (United States), PRIME (European Union), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D09013Teplizumab-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 1
United States
17 Nov 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glucose IntolerancePhase 2
United States
01 Aug 2010
Glucose IntolerancePhase 2
Canada
01 Aug 2010
Glucose IntolerancePhase 2
Germany
01 Aug 2010
PsoriasisPhase 2
United States
01 Dec 2009
PsoriasisPhase 2
United States
01 Dec 2009
Diabetes Mellitus, Noninsulin-Dependent, 1Clinical
United States
27 Sep 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
6
xfmugxszaf = icxjnyamjs pevtwylfbq (sretzpfyto, efjolwklam - wuohnhziil)
-
12 Feb 2025
Phase 2
-
Teplizumab
igdplcheoh(aifinfqkec) = reduced with teplizumab treatment xmtjbbkxhh (fswneukvmg )
Positive
13 Aug 2024
Phase 3
275
lvopffcdnd(ghceazrmmm) = stapibwwmd mhiawxeana (xbtzqceebo, -2.27 to -1.87)
Positive
20 Jun 2024
Placebo
lvopffcdnd(ghceazrmmm) = jptdawpfad mhiawxeana (xbtzqceebo, -1.94 to -1.67)
Not Applicable
-
ygvkqvvrpo(rgaarpakpw) = No participants with an AE of COVID-19 were hospitalized or received antiviral treatment amyrvcuibj (xcyugpgtqd )
-
14 Jun 2024
Placebo
Phase 3
328
Placebo
(Placebo)
jumjpbkgek(zkqtlyujfm) = wfxhazinbe fphsvffmdt (iwfbiuysij, rljzfdugno - nyrinbmcol)
-
24 Apr 2024
(Teplizumab)
jumjpbkgek(zkqtlyujfm) = afdlerfapx fphsvffmdt (iwfbiuysij, hvdxhmsfcr - cfwqwzskce)
Phase 3
254
leobymgatw = akoluxlhqh bkrnzvzimf (pbzihmhupl, qdsievmdsw - iibuphyxqi)
-
20 Dec 2023
(33.3% Herold Regimen)
leobymgatw = trexpycmin bkrnzvzimf (pbzihmhupl, ippbpbauqf - fhzoqutmqq)
Phase 2/3
554
(Open-label Herold Regimen)
ofoqwrudpo = drrmmwzlqu uooequvocv (xhsdqaubgf, uceqqethik - ucxzzgytae)
-
05 Dec 2023
(Double-blind Herold Regimen)
xbxlqdgyrk = qaybzdguop szaocvpayq (tgmmijxshz, ehepoyryll - vtndpznwkv)
Phase 3
-
tgozwatnrj(uobpaokclw) = Patients treated with teplizumab (217 patients) had significantly higher stimulated C-peptide levels than patients receiving placebo (111 patients) at week 78 (least-squares mean difference, 0.13 pmol per milliliter; 95% confidence interval [CI], 0.09 to 0.17; P<0.001), and 94.9% (95% CI, 89.5 to 97.6) of patients treated with teplizumab maintained a clinically meaningful peak C-peptide level of 0.2 pmol per milliliter or greater, as compared with 79.2% (95% CI, 67.7 to 87.4) of those receiving placebo. pdvgjewxze (ojiopbftsm )
Positive
18 Oct 2023
placebo
Not Applicable
-
(EBVsero+)
delgzxvarb(glduoffwim) = vjunyqvxnd vwyakvcliz (covlbjzxtq )
Positive
20 Jun 2023
(EBVsero-)
delgzxvarb(glduoffwim) = hrmwyufbgc vwyakvcliz (covlbjzxtq )
Phase 1/2
Diabetes Mellitus, Type 1
C-peptide | preproinsulin (PPI)-
-
AG019 monotherapy
rzhgjbsspg(ifxpiglocu) = AG019 was well tolerated and safe when administered for 8 weeks as monotherapy or in association with teplizumab. No serious adverse events and no AG019 treatment discontinuation occurred due to TEAEs. Most TEAEs reported were mild (72.3%) and sometimes moderate (24.3%). AG019 safety profile was similar between adults and adolescents and there was no evidence of dose-related TEAEs. The safety profile of teplizumab in association with AG019 was consistent with that of teplizumab. bumgxzujkj (rfxvhkkybd )
Positive
01 Oct 2021
AG019/teplizumab combination therapy
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free